期刊文献+

PTEN、p21基因在新疆哈萨克族食管癌中的表达 被引量:2

Expressions of PTEN and p21 Genes in Hazak Patients with Esophageal Cancer
下载PDF
导出
摘要 目的研究PTEN、p21基因在哈萨克族食管癌中的表达。方法采用RT-PCR法检测PTEN、p21基因在48例哈萨克族食管癌组织及远端无癌组织中的表达,并分析其表达与肿瘤分化、TNM分期、临床分期、淋巴结转移的关系。结果 PTEN基因在癌组织和远端无癌组织中的表达阳性率分别为75%、45.8%,癌组织高于远端无癌组织(χ2=8.537,P<0.05);p21基因在癌组织和远端无癌组织中表达的阳性率分别为95.8%、97.9%,差异无统计学意义(χ2=0.344,P>0.05)。PTEN和p21表达与食管癌分化程度、不同浸润深度及有无淋巴结转移均无相关性。结论 PTEN、p21基因可能均不是哈萨克族食管癌的主要致病基因。 Objective To investigate the expressions of PTEN and p21 genes in Hazak patients with esophageal cancer. Methods The expressions of PTEN and p21 genes were detected by RT-PCR in 48 samples (cancer tissues and normal tissues) of patients with esophageal cancer. The relationship between the expressions of PTEN and p21 genes, tumor differentiation, TNM stage, clinical phase and lymph node metastasis were analyzed. Results The positive rates of PTEN gene were 75% and 45.8% in cancer and distant normal tissues. The expression of PTEN was significantly higher in cancer tissues than that of distant normal tissues (X%8.537, P 〈 0.05). The positive rates of p21 gene were 95.8% and 97.9% in cancer and distant normal tissues, and no significant difference between them (x^2=0.344, P 〉 0.05). There was no correlation between expressions of PTEN and p21and the tumor differentiation, the depth of invasion and lymph node metastasis in esophageal cancer. Conclusion PTEN and p21 genes are not the primary genes for the carcinogenesis of esophageal cancer in Hazak.
出处 《天津医药》 CAS 北大核心 2013年第9期852-854,共3页 Tianjin Medical Journal
基金 国家自然科学基金资助项目(项目编号:30950012)
关键词 鳞状细胞 食管肿瘤 逆转录聚合酶链反应 基因 肿瘤抑制 原癌基因蛋白质p21(ras) 基因表达 PTEN 哈萨克族 carcinoma, squamous cell esophageal neoplasms RT-PCR gene, tumor suppressor proto-oncogene proteins p2 l(ras) gene expression PTEN Hazak
  • 相关文献

参考文献8

二级参考文献45

共引文献28

同被引文献24

  • 1王立东.食管和贲门癌癌变多阶段演进机制[J].中华肿瘤防治杂志,2006,13(5):321-324. 被引量:33
  • 2来茂德.肿瘤的分子分型(类)和诊治[J].浙江大学学报(医学版),2006,35(4):349-353. 被引量:3
  • 3Shirai K, Tamaki Y, Kitamoto Y, et al. Prognosis was not de- teriorated by multiple primary cancers in esophageal cancer patients treated by radiotherapy[J]. J Radiat Res, 2013, 54 (4): 706-711.
  • 4Tomimaru Y, Eguchi H, Nagano H, et al. Circulating mi- croRNA-21 as a novel biomarker for hepatocellular carcino- ma[J]. J Hepatol, 2012, 56(1):167-175.
  • 5Hari DM, Leung AM, Lee JH. et al. AJCC cancer staging manual 7th edition criteria for colon cancer: Do the com- plex modifications improve prognostic assessment?[J]. J Am Coil Surg, 2013, 217(2): 181-190.
  • 6Atsumi K, Shioyama Y, Arimura H, et al. Esophageal steno- sis associated with tumor regression in radiotherapy for esophageal cancer: frequency Oncol Biol Phys, 2012, 82(5) and prediction[J]. Int J Radiat 1973-1980.
  • 7Nomura M, Shitara K, Kodaira T, et al. Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy[J]. Int J Radiat Oncol Biol Phys, 2012, 82(2): 946-952.
  • 8Swisher SG, Winter KA, Komaki RU, et al. A phase II study of a paclitaxel-based chemoradiation regimen with se- lective surgical salvage for resectable locoregionally ad- vanced esophageal cancer: Initial reporting of RTOG 0246 [J]. lnt J Radiat Oncol Biol Phys, 2012, 82(5): 1967-1972.
  • 9Caponi S, Funel N, Frampton AE, et al. The good, the bad and the ugly: A tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms[J]. Ann Oncol, 2013, 24(3): 734-741.
  • 10Androsavich JR, Chau BN, Bhat B, et al. Disease-linked microRNA-21 exhibits drastically reduced mRNA binding and silencing activity in healthy mouse liver[J]. RNA, 2012, 18(8): 1510-1526.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部